Tecserena

Tecserena is a Swiss biotechnology company and a spin-off from the University of Zurich, dedicated to the discovery and development of therapies targeting cellular senescence. The company leverages a proprietary drug discovery platform to identify senolytic agents—compounds that selectively eliminate senescent cells—and senomorphic agents that modulate their activity. Tecserena's initial focus is on oncology, specifically targeting senescent cells in B-cell lymphomas to overcome treatment resistance and improve long-term survival. Beyond cancer, the company explores the potential of its platform to address various age-related pathologies driven by the accumulation of senescent cells. By integrating advanced molecular biology with high-throughput screening, Tecserena aims to translate senescence research into transformative clinical treatments.